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Classification of Focal Prostatic Lesions
on Transrectal Ultrasound (TRUS) and the
Accuracy of TRUS to Diagnose Prostate
Cancer
Objective: To improve the diagnostic efficacy of transrectal ultrasound
(TRUS)-guided targeted prostatic biopsies, we have suggested the use of a new
scoring system for the prediction of malignancies regarding the characteristics of
focal suspicious lesions as depicted on TRUS.
Materials and Methods: A total of 350 consecutive patients with or without
prostate cancer who underwent targeted biopsies for 358 lesions were included
in the study. The data obtained from participants were randomized into two
groups; the training set (n = 240) and the test set (n = 118). The characteristics of
focal suspicious lesions were evaluated for the training set and the correlation
between TRUS findings and the presence of a malignancy was analyzed.
Multiple logistic regression analysis was used to identify variables capable of pre-
dicting prostatic cancer. A scoring system that used a 5-point scale for better
malignancy prediction was determined from the training set. Positive predictive
values for malignancy prediction and the diagnostic accuracy of the scored com-
ponents with the use of receiver operating characteristic curve analysis were
evaluated by test set analyses.
Results: Subsequent multiple logistic regression analysis determined that
shape, margin irregularity, and vascularity were factors significantly and indepen-
dently associated with the presence of a malignancy. Based on the use of the
scoring system for malignancy prediction derived from the significant TRUS find-
ings and the interactions of characteristics, a positive predictive value of 80% was
achieved for a score of 4 when applied to the test set. The area under the receiv-
er operating characteristic curve (AUC) for the overall lesion score was 0.81.
Conclusion: We have demonstrated that a scoring system for malignancy pre-
diction developed for the characteristics of focal suspicious lesions as depicted
on TRUS can help predict the outcome of TRUS-guided biopsies.
ransrectal ultrasound (TRUS) is generally recognized as the method of
choice for prostatic biopsy guidance, however, only 20% of urologists
perform targeted biopsies based on sonographic findings (1, 2). Most
contemporary prostate biopsy protocols have concentrated on the use of the system-
atic prostate biopsy approach and currently require the acquisition of 10 or more cores
(3). Ultrasound (US) criteria used to identify and characterize suspicious lesions for
diagnosing a malignancy are controversial and have not been well defined (1, 4).
Moreover, the low positive predictive value (PPV) for the presence of prostate cancer
remains a considerable weakness (5, 6). Although increased cancer detection has been
reported for the use of color Doppler US (7, 8), the combined sensitivity of gray-scale
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Tand color Doppler imaging is insufficient to preclude the
need for systemic biopsies (6, 9). Recently, identification of
prostatic lesions with the use of TRUS has been re-
emphasized in recently published studies. Djavan and
Margreiter (10) have suggested that taking the endosono-
graphic morphology of the prostate gland into considera-
tion for prostate biopsy strategies may improve the quality
of the prostate biopsy. Furthermore, according to Shim et
al. (11), men with suspicious lesions depicted on TRUS had
a higher risk of being diagnosed with prostate cancer.
The purpose of this study was to suggest the use of a new
scoring system for malignancy prediction for focal
suspicious lesions depicted on TRUS and to evaluate  the
diagnostic efficacy including determination of the PPV for
TRUS guided biopsies. In the current study, we developed
a new scoring system for malignancy prediction by using
TRUS results from a training set of patients. We then
evaluated the reliability of the criteria by applying the
criteria in a “blinded” fashion to a test set of patients.
MATERIALS AND METHODS
Our Institutional Review Board approved this retrospec-
tive study and waived the requirement for patient
informed consent.
Patients
Among patients referred for TRUS with abnormal
prostate specific antigen (PSA) levels (> 3.0 ng/mL) or a
palpable abnormality detected on a digital rectal examina-
tion (DRE) between July 2003 and December 2005, 350
consecutive patients underwent a targeted prostate biopsy
for 358 suspicious lesions and were included in this study.
Of these patients, 147 patients had prostatic cancer (mean
age, 69.7 ± 8.0 years; age range, 49-94 years) and 203
patients had no malignancy (mean age, 64.1 ± 8.6 years;
age range, 33-85 years).
Patients and accompanying data were randomized into
two groups; the training set (236 patients with 240 lesions)
and the test set (114 patients with 118 lesions). Clinical
profiles of the patients showed no statistically significant
differences between the two groups (Table 1).
US Examination and Interpretation
Transrectal US was performed by a uroradiologist with
more than 10 years of uroradiology experience with the
use of an iU 22 or HDI 5000 ultrasound scanner (Philips,
Bothell, WA) equipped with a 9-4 MHz broadband curved
array endocavitary transducer. TRUS included imaging in
the transverse and sagittal planes using both gray-scale and
color Doppler US. Gray-scale imaging was performed first,
followed by color Doppler US imaging. The color window
sector width was increased to include the entire transverse
width of the gland. To optimize low-velocity flow
detection, the pulse repetition frequency was set to 800 Hz
with a wall filter of 50 Hz.
The following US characteristics of focal suspicious
lesions in the training set (n = 240) were evaluated
retrospectively by two radiologists in consensus, blinded to
the pathological findings. The characteristics included
unilaterality, location, echotexture, outline, definition,
shape, vascularity and contour bulging. Lesion location
was reported as “outer” when a lesion was located at the
outer half of the peripheral zone, as “inner” when a lesion
was located at the inner half of the peripheral zone or at
the transition zone, or as “both” when a lesion was located
in both halves of the peripheral zone. Echotexture was
classified as homogeneous or heterogeneous. Lesion
margin outline was classified as regular or irregular. The
term “regular” was used only if a nodular lesion was round
or oval. Lesions were classified as well-defined or ill-
defined. In terms of lesion shape, three shapes were identi-
fied: nodular, band-like and clusters (i.e., clusters of
millimetric foci). During color Doppler US examinations,
blood flow patterns and intensities were evaluated for all
of the lesions. Doppler amplification was controlled so that
normal prostatic tissue did not display any noise. Positive
contour-bulging was defined as asymmetric bulging of the
contour of the prostate.
After US examinations, biopsies of suspicious lesions
both for the training set and test set were performed by a
radiologist using an automatic core biopsy device (Pro-Mag
2.2, Manan Medical Products, Northbrook, IL). In addition
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Table 1. Randomization of Patients by Stratified Random
Sampling
Training Set Test Set P value
Total patients 236 114
Age (years) 68.0  8.50 67.0  9.30 NS
PSA (ng/ml) 07.2  3.500 8.0  4.20 NS
Abnormal DRE 062 (26%) 30 (26%) NS
Positive biopsy 101 (43%) 46 (40%) NS
Patients with cancer 101 46
Gleason score 6.9  0.9 07.1  1.08 NS
Gleason score  7 078 (77%) 36 (78%) NS
Cancer length (cm) 0.8  0.7 0.8  0.6 NS
Core length (cm) 1.5  0.3 1.5  0.4 NS
% cancer length 0.57  67.7 0.52  33.6 NS
Note.─ PSA = prostate-specific antigen, DRE = digital rectal examination, 
NS = not statistically significant
Data presented are median  standard deviation or number.to twelve randomized biopsies, an additional prostate
biopsy was performed targeting focal suspicious lesions.
Pathology reports about targeted focal suspicious lesions
were evaluated.
Data Analysis
For each of the US criteria (i.e., unilaterality, location,
echotexture, outline, lesion definition, shape, vascularity
and prostate contour), PPV, sensitivity and specificity for
the detection of malignant lesions were calculated using
standard procedures for the training set. Statistical signifi-
cance was calculated using the chi-squared test and p
values of < 0.05 were considered to indicate statistical
significance. To determine which US finding best depicted
prostate cancer, multiple logistic regression analysis was
used to examine each US finding. The backward stepwise
elimination technique was used to remove non-significant
interactions. SPSS for Windows version 11.0 (SPSS,
Chicago, IL) was used to perform all statistical computa-
tions.
Scoring System for Focal Suspicious Lesions Seen on
Transrectal US
Two of the investigators developed a new diagnostic
scoring system using US findings that were suggestive for
the presence of a malignancy from the training set and
scored 118 focal suspicious lesions seen on TRUS for the
test set based on the use of the proposed scoring system.
PPVs for the use of a five-point scale were calculated for
malignancy and benignity. PPVs for malignancy and
benignity of focal suspicious lesions in patients with a PSA
of < 10 ng/mL were assessed. In addition, the diagnostic
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+ PPV  Sensitivity  Specificity 
(% of 101) (% of 139) (%) (%) (%)
P value
Unilaterality
Unilateral 83 (82) 109 (78) -- - 0.317
Bilateral or mid-portion 17 (17) 030 (22)
Location*
Outer 74 (73) 115 (83) -- - < 0.001
Inner 9 (9) 020 (14)
Both 18 (18) 04 (3)
Echotexture
Homogeneous 84 (83) 125 (90) -- - 0.052
Heterogeneous 17 (17) 014 (10)
Outline (margin)
Regular 19 (19) 079 (57) -- - < 0.001
Irregular 82 (81) 060 (43)
Definition
Well-defined 47 (47) 077 (55) -- - 0.084
Ill-defined 54 (54) 062 (45)
Shape
Nodular 36 (36) 053 (38) -- - < 0.001
Band-like 36 (36) 074 (53)
Clusters 29 (29) 12 (9)
Vascularity 72 (71) 043 (31) 62.6 71.3 69.0 < 0.001
Vascularization pattern (% of 72) (% of 43)
Intra-lesional 49 (68) 025 (58) -- - < 0.001
Peri-lesional 21 (29) 018 (42)
Both 2 (3) 00 (0)
Contour-bulging 19 (19) 023 (17) 45.2 18.8 83.5 0.629
Detection in two planes (% of 78) (% of 96) 0.588
Detection for both planes 68 (87) 081 (84)
Detection only at the axial plane 10 (13) 015 (16)
Note.─ PPV = positive predictive value
*Location was described as “outer” when lesion was limited to outer peripheral zone and was reported as “inner” if lesion was limited to inner peripheral
zone or to transition zone. When lesion involved all sides of peripheral zone, it was described as “both”.
+Data are presented as counts, with corresponding percentages in parentheses.accuracy of the scored components was determined with
the use of receiver operating characteristic curve (ROC)
analysis. PPV differences between malignancy and
benignity for each of the scores of the five-point scale were
statistically evaluated using the chi-squared test. The PPV
of a systemic biopsy only and systemic biopsy plus
targeted biopsy were calculated on a per-patient basis, and
were statistically compared with the use of McNemar’s
test.
RESULTS
Evaluation of the US Findings of Lesions Determined
as Suspicious by the Use of Transrectal US in the
Training Set
Of the US characteristics evaluated for all suspicious
lesions, location, shape, outline, vascularity and vascular
pattern were found to be statistically significant indicators
for the presence of prostate cancer (Table 2). An inner
location was found in 14% of benign lesions and in 9% of
malignant lesions (x
2 test, p < 0.001). A statistically signifi-
cant difference was also found for the number of lesions
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Fig. 1. Scoring system for focal suspicious lesions.
A, B. Findings for 45-year-old male are presented. Transrectal US image shows band-like low echoic lesion (arrows) with regular outline
at outer peripheral zone. Color Doppler US shows prominent hypervascularity (arrows) within lesion, indicating likelihood of malignancy.
However, based on use of algorithm for scoring, lesion was given score 2, and positive predictive value for benignity was higher than that
for malignancy (64.7% versus 35.3%). Pathology revealed no evidence of malignancy in prostate biopsy samples.
AB
Table 3. Evaluation of Scoring System for Focal Suspicious Lesions Depicted on Transrectal US
Score Malignant Lesions Benign Lesions PPV (%)** Total (%)*
Total cases 4 20 05 80 25 (21)
3 17 18 49 35 (30)
2 12 22 35 34 (29)
1 022 1 09 23 (20)
0 00 01 000. 1 (1)
Total 51 67 118
PSA < 10.0 ng/mL 4 05 05 50 10 (14)
3 09 16 36 25 (34)
2 05 16 24 21 (29)
1 011 5 06 16 (22)
0 00 01 00 1 (1)
Total 20 53 73
Note.─ PPV = positive predictive value, PSA = prostate specific antigen
*Data are presented as counts, and corresponding percentages in parentheses. **P value < 0.001 by chi-square testwith a band-like shape, which was more often present in
benign lesions (53.2%) than in malignant lesions (35.6%;
x
2 test, p < 0.001). Furthermore, an irregular outline was
observed for 81% of malignant lesions and for 43% of
benign lesions (x
2 test, p < 0.001). In addition, it was
determined that vascularity was associated with prostate
cancer. Increased vascularity was found in 71% of
malignant lesions but in only 31% of benign lesions (x
2
test, p < 0.001).
Multivariate Logistic Regression Analysis
Multivariate logistic regression analysis was performed
for all of the US characteristics. When all of the lesions
were evaluated, three criteria, including lesion shape
(nodular or cluster), an irregular margin and increased
vascularity were found to be significantly and indepen-
dently associated with the presence of prostate cancer (p <
0.001).
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Fig. 1. Scoring system for focal suspicious lesions.
C, D. Findings for 70-year-old male are presented. Transrectal US image shows cluster-like hypoechogenic lesion (arrows) at right outer
peripheral zone. Color Doppler US image shows no definite vascularity (arrows) within lesion, indicating that lesion is probably benign.
However, devised algorithm classified lesion with score 3, which has considerable positive predictive value for malignancy (48.6%).
Pathology confirmed lesion as prostatic cancer.
E, F. Findings for 75-year-old male are presented. Transrectal US image shows nodular low echogenic lesion (arrows) in left prostate.
Portion of this lesion was located in transition zone, although most of lesion was located at inner peripheral zone. Color Doppler US
image shows focal prominent vascularity (arrows) within lesion. This lesion corresponded to score 2, and pathology revealed lesion as
due to prostatic cancer.
EFScoring System for Focal Suspicious Lesions and
Application to the Test Set
The three criteria identified above by the use of multiple
logistic regression analysis were selected as new criteria
and location (identified by the chi-squared test) was added
as a fourth criterion. Figure 1 shows the scoring system
using a 5-point scale for focal suspicious lesions identified
by TRUS.
The algorithm determines how many features are present
among the following four criteria: a nodular or cluster
shape, an irregular outline, increased vascularity and
extension to the outer side of peripheral zone; a score of
one is added for each trait. Sensitivity, specificity, positive
and negative predictive values for the prediction of
malignancy were evaluated by applying the scoring system
to the test set (n = 118). Each of the scores for the five-
point scale showed statistically significant differences
between malignant and benign lesions (Table 3). In
addition, for the use of the above algorithm, cases with
PSA values of < 10 ng/mL were also shown to be signifi-
cantly associated with the presence of a malignancy,
especially for a score of 4 (Table 3). The area under the
receiver operating characteristic curve (AUC) for the
overall lesion score was 0.81 (Fig. 2).
The PPVs for a systemic biopsy alone and a systemic
biopsy plus a targeted biopsy are summarized in Table 4.
By adding the targeted biopsy to the systemic biopsy,
prostate cancer was diagnosed in an additional 15 of 114
patients (13.2%), including seven of 23 (30.4%) patients
with a score of 4, five of 34 (14.7%) patients with a score
of 3 and three of 34 (8.8%) patients with a score of 2. In
terms of the PPV for a malignancy, a significant difference
was found between a systemic biopsy alone and systemic
biopsy plus targeted biopsy (all p < 0.05 except for a score
of 0).
DISCUSSION
Even though hypoechoic lesions of the prostate are
frequently detected by the use of TRUS, these lesions have
been shown to correspond to a wide-spectrum of patholo-
gies such as prostatic carcinoma, prostate dysplasia, inflam-
matory changes, granulomatous prostatitis, benign prosta-
tic hyperplastic nodules, smooth muscle bundles, fibrosis or
dilated prostatic ducts or cysts (12). Moreover, while the
sensitivity of TRUS for lesion detection is high, the
specificity of TRUS is disappointingly low and therefore
the modality has limits to differentiate benign and
malignant lesions.
Recently, several investigators have suggested a re-
emphasis of TRUS identification of prostatic lesions.
According to Toi et al. (13), an increase in the cancer
detection rate in patients referred for all indications has
been shown for intraprostatic lesions identified by TRUS
after a targeted prostate biopsy. Biopsy specimens from
these lesions have a greater volume of cancer detected for
each positive core and a higher grade of cancer, which
concurs with our finding that a positive core tissue had a
56% cancer length. Shim et al. (11) and Lee et al. (14)
reported that patients with suspicious lesions depicted on
TRUS had more aggressive features of cancer in a compari-
son to patients without a suspicious lesion. Therefore,
identification and a prostate biopsy of US suspicious
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Table 4. Comparison of Positive Predictive Values for
Malignancy by Use of Systemic Biopsy and
Targeted Biopsy
Positive Predictive Value for Malignancy (%)
Score
Systemic  Systemic + 
P value*
Biopsy Alone Targeted Biopsy
4 52 (12/23)0 83 (19/23)0 0.005
3 32 (11/34)0 38 (13/34)0 0.07
2 27 (9/34)00 35 (12/34)0 < 0.001
1 9 (2/22)0 9 (2/22)0 > 0.99
0 0 (0/1)00 0 (0/1)00 > 0.99
Total 30 (34/114) 40 (46/114) < 0.001
Note.─ This comparison included test set of 114 patients.
Data in parentheses are per patient and are values used to calculate
percentage.
*P values were calculated by use of McNemar’s test.
Fig. 2. Receiver operating characteristic curves of scoring
system.lesions continue to be useful and important.
This study has refocused on the importance of the TRUS
examination to identify and characterize suspicious lesions.
Based on our findings, focal suspicious lesions allocated to
different TRUS findings had different associated diagnostic
accuracies, and these diagnostic accuracies were statisti-
cally significant. In particular, individuals with a relatively
low PSA level (PSA < 10 ng/mL) were also found to have
a significantly different diagnostic accuracy among differ-
ent scores. Therefore, the proposed scoring system we
have described could be used to recruit prostate biopsy
candidates, especially when PSA levels are relatively low
or equivocal. In addition, the proposed scoring system may
be useful to select sites for a targeted prostate biopsy and
to predict malignancies.
Our findings suggest that not only prominent vascularity
but also abnormal gray scale TRUS findings should be
considered together to differentiate chronic inflammation
from a malignancy. Prostatic intraepithelial neoplasia
(PIN), especially high-grade PIN, is accepted as a premalig-
nant lesion and as a precursor of prostate cancer.
Moreover, even though PIN and prostate cancer foci have
reportedly been shown to have similar appearances as
depicted on TRUS, clusters of millimetric hypoechoic foci
may indicate high-grade PIN foci (15). Our results support
findings of previous reports in terms of the significance of
clusters; clusters were found in 29% of malignant lesions
and in 9% of benign lesions (p < 0.001).
Our study has several limitations. The study was limited
inherently by its retrospective design, and there may be a
selection bias. This study also has a potential limitation
with regard to the use of contrast-enhanced color Doppler
imaging. Recent clinical trials have demonstrated improved
prostate carcinoma detection with the use of targeted
biopsies or grading of prostate cancers by the use of
contrast-enhanced color Doppler imaging (16). However,
other studies have demonstrated the importance of training
personnel to interpret properly contrast-enhanced images
due to a high level of false-positive results, which substan-
tially reduce specificity (17). Moreover, cost-effectiveness
must also be considered. Although TRUS findings alone
are limited in terms of prostate cancer detection, we
propose a diagnostic scheme with the use of the scoring
system that can aid decision-making as to whether or not a
patient should undergo a prostate biopsy when focal
suspicious lesions are detected by the use of TRUS.
In conclusion, the use of a scoring system for focal
suspicious lesions as defined in the present study is found
to be associated with different PPVs. The devised scoring
system for focal suspicious lesions depicted on TRUS is
found to improve the PPV for the use of TRUS and to be
helpful to predict the outcomes of TRUS guided biopsies. It
is hoped that the use of our suggested scoring system will
improve diagnostic decision making for focal suspicious
lesions depicted on TRUS. A further controlled prospective
study in a larger population would provide a more detailed
overview of the ability of US examinations to diagnose
prostate cancer and to help decision-making concerning the
need for targeted biopsies.
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